Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: A systematic review and meta-analysis of double-blind, randomized placebo-controlled trials were conducted to examine how soon an increase in recurrence risk could be observed among bipolar I disorder (BDI) patients who were clinically stable with the combination therapy of mood stabilizers with second-generation antipsychotics (SGA+MS) treatment following second-generation antipsychotics discontinuation (i.e., MS alone) compared with SGA+MS maintenance.
Methods: Embase, PubMed, and CENTRAL databases were used for systematic literature searches until May/22/2020. The primary outcome was the recurrence rate of any mood episode at 6 months. The secondary outcomes were the recurrence rates of manic/hypomanic/mixed and depressive episodes and all-cause discontinuation at 6 months. The recurrence rates at 1, 2, 3, 9, and 12 months were also investigated.
Results: Eight studies (mean study duration = 58.25 ± 33.63 weeks) were identified (SGA+MS group [n = 1,456: 3 aripiprazole+MS studies, 1 lurasidone+MS study, 1 olanzapine+MS study, 2 quetiapine+MS studies, 1 ziprasidone+MS study] and placebo+MS group [n = 1,476]). Pooled SGA+MS exhibited lower recurrence rates of any mood episode, manic/hypomanic/mixed episodes, and depressive episodes as well as reduced all-cause discontinuation at every observational point. The risk ratios (95% confidence interval) of the recurrence rate at 6 months were 0.51 (0.39-0.86) for any mood episode, 0.42 (0.30-0.59) for manic/hypomanic/mixed episodes, and 0.39 (0.28-0.54) for depressive episodes. The RR for all-cause discontinuation was 0.67 (0.50-0.89). Both aripiprazole+MS and quetiapine+MS outperformed placebo+MS in the recurrence of any mood, manic/hypomanic/mixed, and depressive episodes at 6 months.
Conclusions: SGA+MS prevented recurrence for up to 12 months for BDI compared with placebo+MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bdi.13053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dopaminergic frontostriatal pathways in major depressive disorder and childhood sexual abuse: a multimodal neuroimaging investigation.
Mol Psychiatry
September 2025
Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, MA, USA.
Dysregulated dopaminergic signaling has been implicated in the pathophysiology of major depressive disorder (MDD) and childhood sexual abuse (CSA), but inconsistencies abound. In a multimodal PET-functional MRI study, harnessing the highly selective tracer [C]altropane, we investigated dopamine transporter availability (DAT) and resting-state functional connectivity (rsFC) within reward-related regions among 112 unmedicated individuals (MDD: n = 37, MDD/CSA: n = 18; CSA no MDD: n = 14; controls: n = 43). Striatal DAT and seed-based rsFC were assessed in the dorsal and ventral striatum and the ventral tegmental area.
View Article and Find Full Text PDFTreatment preferences and self-stigma in depression: Development and validation of the brief ATDT-SF.
J Affect Disord
September 2025
Department of Psychiatry, Psychiatric Centre Copenhagen, Copenhagen, Denmark; Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Patients' beliefs about depression and different antidepressant treatment options may influence help-seeking behaviour, treatment adherence, and ultimately clinical outcomes. The Attitudes Toward Depression and its Treatment (ATDT) questionnaire was developed to assess these attitudes and beliefs; however, subsequent research revealed limitations in its psychometric properties. We sought to develop and validate a shortened version (ATDT-SF) with improved reliability.
View Article and Find Full Text PDFAssociations between age of onset and domain-specific cognitive deficits in major depressive disorder.
J Affect Disord
September 2025
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China. Electronic address:
Background: This study aimed to examine associations between age of onset and domain-specific cognitive deficits in major depressive disorder (MDD).
Methods: We assessed 582 MDD patients (389 first-episode [FED], 193 recurrent [RMD]) and 280 healthy controls (HCs) using five cognitive domains from the MATRICS Consensus Cognitive Battery. Of these patients, 289 were reassessed after 8 weeks of antidepressant treatment.
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.
Eur Neuropsychopharmacol
September 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently used for metabolic conditions, have demonstrated potential antidepressant effects via neuromodulatory pathways. This systematic review aims to provide evidence on the antidepressant effects of GLP-1 RAs and elucidate their underlying mechanism of action.
Methods: We examined studies that investigated the effect of GLP-1 RAs on depressive symptoms.
Hyperhomocysteinemia in chronic schizophrenia: prevalence, clinical correlates, and paradoxical associations with symptom severity.
Eur Arch Psychiatry Clin Neurosci
September 2025
Tianjin Anding Hospital, Institute of Mental Health, Psychiatric Medical Center of Tianjin University, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China.
Background: Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), have been implicated in the pathophysiology of schizophrenia. Most prior studies focused on first-episode or acute-phase schizophrenia patients, leaving the prevalence, determinants, and clinical correlates of HHcy in chronic schizophrenia understudied. This study aims to investigate the prevalence and determinants of HHcy in patients with chronic schizophrenia, as well as its clinical correlates.
View Article and Find Full Text PDF